Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT02893761
Recruiting Observational

Bergonie Institute Breast Cancer Database

NCT02893761 · tracked via the Priya Life Science France tracker
Sponsor
Institut Bergonié
Phase
Observational
Started
1990-01
Last updated
2025-09-23

Condition(s) studied

Breast Cancer

Study summary

A database of breast cancer patients was established at Institute Bergonié since the 90s , to assess patients' survival, assess practice, search for prognostic factors.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Breast cancer * Aged 18 years and over * First treatment at Bergonie Institute Exclusion Criteria: \-

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institut Bergonié, Comprehensive Cancer Center Bordeaux France Recruiting

More Institut Bergonié trials in France

High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study Recruiting
Definition for the Assessment of Time-to-event Endpoints in CANcer Trials (DATECAN-1) Active, not recruiting
Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer Recruiting
CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. Recruiting
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Recruiting

Other trials for the same condition

Reproductive Health in Breast Cancer Survivor Active, not recruiting
Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI Recruiting
Identification of New Prognostic Markers for Breast Cancer. Recruiting
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer Active, not recruiting
Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02893761 on ClinicalTrials.gov ↗ ← All trials in France